AI Protein Structure Cancer Drug Target Discovery

Deep Learning Architectures for Cancer Protein Tertiary Structure Prediction

This research investigates transformer-based and graph neural network models for predicting three-dimensional structures of cancer-associated proteins with high accuracy and computational efficiency. Novel architectures enable discovery of previously unknown binding pockets and allosteric sites critical for rational drug design against oncogenic targets.

Cryo-EM Data Integration with Machine Learning for Tumor Suppressor Characterization

This research combines cryo-electron microscopy datasets with AI-driven image processing and structural annotation to determine native conformations of tumor suppressors like p53 and PTEN. Integrated analysis reveals dynamic conformational states and post-translational modification sites essential for understanding cancer biology and identifying therapeutic vulnerabilities.

Mutational Landscape Mapping of Cancer Protein Structural Stability and Druggability

This research applies machine learning to systematically predict how cancer-driving mutations alter protein folding stability, binding interfaces, and ligand accessibility across the proteome. Comprehensive mutational maps generate predictive models that distinguish oncogenic mutations affecting drug-target interactions from neutral variants.

Artificial Intelligence Prediction of Protein-Protein Interaction Networks in Oncogenic Signaling

This research develops graph-based neural networks to predict cancer-relevant protein-protein interactions and identify critical regulatory hubs in MAPK, PI3K, and Wnt signaling pathways. AI-predicted interaction networks reveal synthetic lethal dependencies and non-obvious multi-target combination strategies for cancer therapy.

Structural Dynamics Simulation of Kinase Domains Under Allosteric Inhibitor Binding

This research uses physics-informed neural networks and molecular dynamics acceleration to simulate conformational changes in cancer kinases responding to allosteric drug binding. Enhanced simulations reveal mechanism-of-action pathways and predict resistance mutations before clinical emergence.

Fragment-Based Drug Design Optimization Using Protein Structure Prediction AI

This research leverages high-resolution protein structure predictions to rapidly identify optimal small molecule fragments that bind cryptic cancer protein pockets with minimal binding entropy penalties. Fragment optimization pipelines accelerate lead compound identification and minimize off-target toxicity through structure-guided design.

Ensemble Machine Learning for Predicting Cancer Protein Thermal Stability and Degradation

This research develops ensemble algorithms combining structural features, biophysical parameters, and sequence information to predict proteolytic vulnerability and degradation kinetics of oncogenic proteins. Thermal stability predictions enable rational design of PROTAC and molecular glue degrader compounds.

Evolutionary Sequence-Structure Covariation Analysis of Cancer Driver Protein Families

This research applies covariation analysis and phylogenetic deep learning to identify structurally constrained regions and functional hotspots within cancer protein families across species evolution. Evolutionary insights reveal conserved druggable features and predict functional consequences of patient-specific mutations.

Autonomous AI-Driven Structure-Based Virtual Screening for Oncology Bioactive Compound Libraries

This research implements end-to-end deep learning pipelines that perform autonomous docking, binding affinity prediction, and ADMET assessment against cancer protein targets at scale. Automated screening workflows identify novel chemical matter with improved druglike properties and reduced false-positive rates.

Structural Biomarker Discovery Through Conformational Heterogeneity Analysis of Tumor Proteins

This research uses AI-driven analysis of protein conformational ensembles to identify structure-based biomarkers predictive of drug response and resistance mechanisms in cancer patients. Conformational heterogeneity signatures enable patient stratification and personalized precision oncology treatment selection.